Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
Psilocybin for Major Depressive Disorder: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials Publisher



S Aghajanian SEPEHR ; A Shafiee ARMAN ; S Parvizi Omran SAMIRA ; A Rezaeinejad AIDA ; K Jafarabady KYANA ; O Kohandel Gargari OMID ; S Rajai Firouzabadi SHAHRYAR ; I Mohammadi IDA ; T Bahrami Babaheidari TOURAN ; M Bakhtiyari MAHMOOD
Authors

Source: Journal of Psychopharmacology Published:2024


Abstract

Background: Due to the unsatisfactory therapeutic effects of current antidepressants, research has been launched into alternative treatment approaches, such as the administration of psychedelics. Psilocybin, a classic hallucinogen, has been shown to exert considerable positive influence on depression symptoms through its serotonergic and glutamatergic effects. This systematic review and meta-analysis aimed to evaluate the effectiveness of psilocybin in treating depression. Methods: A comprehensive search of Medline (via PubMed) and the Cochrane Library databases was conducted to identify relevant studies. Inclusion criteria were applied to select studies that investigated the therapeutic impact of psilocybin on depression. A mixed-effects multi-level model was used to estimate the overall effect size. Effectiveness over time was also investigated as a secondary analysis. Results: The results of the primary analysis revealed a large and clinically observable reduction (SMC: −1.24, 95%CI: −1.83 to −0.65, I2level2 = 11.39%, I2level3 = 77.67%) of depressive symptomatology in patients receiving psilocybin in addition to supportive therapy compared to baseline measurements. The decrease was also marked when compared to placebo (p-value = 0.032). The results remained significant even when a secondary analysis assessed the effect in various time intervals since the administration of psilocybin. Conclusion: This systematic review and meta-analysis substantiate the claim that psilocybin is superior in treating depression compared to established psychotherapy alone used for treating depression. This finding warrants further studies with larger sample sizes and across a longer timeframe. © 2024 Elsevier B.V., All rights reserved.
Related Docs
View other Related Docs
1. The Effect of Psychedelics on the Level of Brain-Derived Neurotrophic Factor: A Systematic Review and Meta-Analysis, Journal of Psychopharmacology (2024)
2. The Effects of Lysergic Acid Diethylamide (Lsd) on the Positive Valence Systems: A Research Domain Criteria (Rdoc)-Informed Systematic Review, CNS Drugs (2023)
3. Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Journal of Clinical Pharmacy and Therapeutics (2017)
Experts (# of related papers)
View all Related Experts
Shahin Akhondzadeh Basti (11)
Mohammad Arbabi (2)
Other Related Docs
4. Cilostazol As an Adjunctive Treatment in Major Depressive Disorder: A Pilot Randomized, Double-Blind, and Placebo-Controlled Clinical Trial, Psychopharmacology (2022)
5. Comparison of Vortioxetine and Sertraline for Treatment of Major Depressive Disorder in Elderly Patients: A Double-Blind Randomized Trial, Journal of Clinical Pharmacy and Therapeutics (2020)
6. Does Oral Administration of Ketamine Accelerate Response to Treatment in Major Depressive Disorder? Results of a Double-Blind Controlled Trial, Journal of Affective Disorders (2018)
7. Efficacy and Safety of Pentoxifylline Combination Therapy in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, International Clinical Psychopharmacology (2021)
8. Efficacy of Gemfibrozil As an Adjunct to Sertraline in Major Depressive Disorder, a Double-Blind, Randomized, and Placebo-Controlled Clinical Trial, Iranian Journal of Psychiatry (2021)
9. Psychedelics in the Treatment of Neurologic and Psychiatric Disorders: Coincidence or a New Point of View, Molecular Neurobiology (2025)
10. L-Theanine Adjunct to Sertraline for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Affective Disorders (2023)
11. The Antidepressant Effects of Lavender (Lavandula Angustifolia Mill.): A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials, Complementary Therapies in Medicine (2021)
12. Adjunctive Antidepressants for the Treatment of Bipolar Depression: An Updated Meta-Analysis of Randomized Clinical Trials, Asian Journal of Psychiatry (2024)
13. Selective Serotonin Reuptake Inhibitors in Major Depression Disorder Treatment: An Umbrella Review on Systematic Reviews, International Journal of Psychiatry in Clinical Practice (2020)
14. Crocus Sativus (Saffron) Adjunct to Risperidone for Negative Symptoms of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial, International Clinical Psychopharmacology (2024)
15. Efficacy and Safety of Oral Ketamine Versus Diclofenac to Alleviate Mild to Moderate Depression in Chronic Pain Patients: A Double-Blind, Randomized, Controlled Trial, Journal of Affective Disorders (2016)
16. Adjuvant Thiamine Improved Standard Treatment in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, and Placebo-Controlled Clinical Trial, European Archives of Psychiatry and Clinical Neuroscience (2016)
17. The Accuracy of the Patient Health Questionnaire-9 Algorithm for Screening to Detect Major Depression: An Individual Participant Data Meta-Analysis, Psychotherapy and Psychosomatics (2020)
18. Cinnamomum Tamala As an Adjuvant Therapy in the Treatment of Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial With Placebo Control, Advances in Integrative Medicine (2020)
19. Clinician Guidelines for the Treatment of Psychiatric Disorders With Nutraceuticals and Phytoceuticals: The World Federation of Societies of Biological Psychiatry (Wfsbp) and Canadian Network for Mood and Anxiety Treatments (Canmat) Taskforce, World Journal of Biological Psychiatry (2022)
20. Temperament and Character As a Predictor of Response to Selective Serotonin Reuptake Inhibitors in Patients With Majordepressive Disorder, Archives of Psychiatry and Psychotherapy (2022)